BioNTech (BNTX) is a publicly traded Healthcare sector company. As of May 20, 2026, BNTX trades at $90.36 with a market cap of $22.47B and a P/E ratio of 0.00. BNTX moved +2.64% today. Year to date, BNTX is -6.70%; over the trailing twelve months it is -11.17%. Its 52-week range spans $79.52 to $129.27. Analyst consensus is strong buy with an average price target of $136.36. Rallies surfaces BNTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioNTech Expands Supervisory Board to Eight, Adds Two Oncology Experts: BioNTech's AGM saw 92% of share capital represented as shareholders approved expanding its Supervisory Board from six to eight members and reappointed three existing board members. Two new directors, Iris Löw-Friedrich and Susanne Schaffert, were elected and Helmut Jeggle was chosen as Supervisory Board chairman.
| Metric | Value |
|---|---|
| Price | $90.36 |
| Market Cap | $22.47B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 2.13% |
| 52-Week High | $129.27 |
| 52-Week Low | $79.52 |
| Volume | 760.76K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
15 analysts cover BNTX: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $136.36.